Recombinant Tissue Plasminogen Activator Increases Blood-Brain Barrier Disruption in Acute Ischemic Stroke: An MR Imaging Permeability Study

References

1. 1.↵
   1. del Zoppo G,
   2. von Kummer R,
   3. Hamann GF

   . Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998;65:1–9

   FREE Full Text
2. 2.↵
   1. Smith W,
   2. Sung G,
   3. Starkman S,
   4. et al

   . Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432–38

   Abstract/FREE Full Text
3. 3.↵
   1. Lyden P,
   2. Zivin JA

   . Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Met Rev 1993;5:1–16
4. 4.↵
   Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke: The NINDS tPA Stroke Study Group. Stroke 1997;28:2109–18

   Abstract/FREE Full Text
5. 5.↵
   1. Larrue V,
   2. von Kummer R,
   3. del Zoppo G,
   4. et al

   . Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957–60

   Abstract/FREE Full Text
6. 6.↵
   1. Toni D,
   2. Fiorelli M,
   3. Bastianello S,
   4. et al

   . Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996;46:41–45

   Abstract/FREE Full Text
7. 7.↵
   1. Hacke W,
   2. Kaste M,
   3. Fieschi C,
   4. et al

   . Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–25

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Hacke W,
   2. Kaste M,
   3. Fieschi C,
   4. et al

   . Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245–51

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Jaillard A,
   2. Cornu C,
   3. Durieux A,
   4. et al

   . Hemorrhagic transformation in acute ischemic stroke: The MAST-E study. Stroke 1999;30:1326–32

   Abstract/FREE Full Text
10. 10.↵
    Thrombolytic therapy with streptokinase in acute ischemic stroke: The Multicenter Acute Stroke Trial Europe Study Group. N Engl J Med 1996;335:145–50

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Hacke W,
    2. Kaste M,
    3. Bluhmki E,
    4. et al

    . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Baron J,
    2. von Kummer R,
    3. del Zoppo GJ

    . Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1999;30:180–82

    Abstract/FREE Full Text
13. 13.↵
    1. Furlan A,
    2. Higashida R,
    3. Wechsler L,
    4. et al

    . Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study—A randomized clinical trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–11

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Hacke W,
    2. Albers G,
    3. Al-Rawi Y,
    4. et al

    . The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute thrombolysis trial with intravenous desmoteplase. Stroke 2006;36:66–73

    CrossRef
15. 15.↵
    1. Rowley H

    . Successful patient selection with DWPW-MRI for IV treatment with desmoteplase at 3–9 hours: DIAS and DEDAS trial results. In: Proceedings of the American Society of Neuroradiology, Toronto, Ontario, Canada, May 21–27, 2005
16. 16.↵
    1. Kassner A,
    2. Roberts T,
    3. Taylor K,
    4. et al

    . Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol 2005;26:2213–17

    Abstract/FREE Full Text
17. 17.↵
    1. Periaswamy S

    . General-Purpose Medical Image Registration [PhD dissertation]. Hanover, NH: Dartmouth College; 2003
18. 18.↵
    1. Roberts H,
    2. Roberts TPL,
    3. Brasch RC,
    4. et al

    . Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–99

    Abstract/FREE Full Text
19. 19.↵
    1. Ewing JR,
    2. Knight RA,
    3. Nagaraja TN,
    4. et al

    . Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of ¹⁴C-sucrose in areas of blood-brain opening. Magn Reson Med 2003;50:283–92

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Stejskal E

    . Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 1965;42:288–92

    CrossRefWeb of Science
21. 21.↵
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2007
22. 22.↵
    1. Cao Y,
    2. Brown SL,
    3. Knight RA,
    4. et al

    . Effect of intravascular-to-extravascular water exchange on the determination of blood-to-tissue transfer constant by magnetic resonance imaging. Magn Reson Med 2005;53:282–93

    CrossRefPubMed
23. 23.↵
    1. Lin K,
    2. Kazmi KS,
    3. Law M,
    4. et al

    . Measuring elevated microvascular permeability and predicting hemorrhagic transformation in acute ischemic stroke using first-pass dynamic perfusion CT imaging. AJNR Am J Neuroradiol 2007;28:1292–98

    Abstract/FREE Full Text
24. 24.↵
    1. Bisdas S,
    2. Hartel M,
    3. Cheong LH,
    4. et al

    . Prediction of subsequent hemorrhage in acute ischemic stroke using permeability CT imaging and a distributed parameter tracer kinetic model. J Neuroradiol 2007;34:101–08

    PubMed
25. 25.↵
    1. Dankbaar JW,
    2. Hom J,
    3. Schneider T,
    4. et al

    . Dynamic perfusion CT assessment of the blood-brain barrier permeability: first pass versus delayed acquisition. AJNR Am J Neuroradiol 2008;29:1671–76

    Abstract/FREE Full Text
26. 26.↵
    1. Rosell A,
    2. Ortega-Aznar A,
    3. Alvarez-Sabin J,
    4. et al

    . Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006;37:1399–406

    Abstract/FREE Full Text
27. 27.↵
    1. Castellanos M,
    2. Leira R,
    3. Serena J,
    4. et al

    . Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40–46

    Abstract/FREE Full Text
28. 28.↵
    1. Montaner J,
    2. Molina CA,
    3. Monasterio J,
    4. et al

    . Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598–603

    Abstract/FREE Full Text
29. 29.↵
    1. Kastrup A,
    2. Gröschel K,
    3. Ringer TM,
    4. et al

    . Early disruption of the blood–brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke 2008;39:2385–87

    Abstract/FREE Full Text
30. 30.↵
    1. Nyormoi O,
    2. Mills L,
    3. Bar-Eli M

    . An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 2003;10:558–69

    CrossRefPubMedWeb of Science